Cadrenal Therapeutics, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023
For the six months, net loss was USD 6.18 million. Basic loss per share from continuing operations was USD 0.55.
Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
0.464 USD | +0.87% | -7.00% | -37.15% |
1st Jan change | Capi. | |
---|---|---|
-37.15% | 7.36M | |
+28.90% | 684B | |
+30.34% | 568B | |
-3.79% | 361B | |
+17.82% | 329B | |
+4.54% | 284B | |
+16.02% | 240B | |
+9.33% | 208B | |
-6.71% | 200B | |
+7.67% | 166B |